332 related articles for article (PubMed ID: 29440379)
1. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
Zhao Y; Liu P; Zhang N; Chen J; Landegger LD; Wu L; Zhao F; Zhao Y; Zhang Y; Zhang J; Fujita T; Stemmer-Rachamimov A; Ferraro GB; Liu H; Muzikansky A; Plotkin SR; Stankovic KM; Jain RK; Xu L
Proc Natl Acad Sci U S A; 2018 Feb; 115(9):E2077-E2084. PubMed ID: 29440379
[TBL] [Abstract][Full Text] [Related]
2. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
3. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.
Chen J; Landegger LD; Sun Y; Ren J; Maimon N; Wu L; Ng MR; Chen JW; Zhang N; Zhao Y; Gao X; Fujita T; Roberge S; Huang P; Jain RK; Plotkin SR; Stankovic KM; Xu L
Nat Protoc; 2019 Feb; 14(2):541-555. PubMed ID: 30617350
[TBL] [Abstract][Full Text] [Related]
4. Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells.
Dilwali S; Roberts D; Stankovic KM
Cancer Biol Ther; 2015; 16(1):170-5. PubMed ID: 25692621
[TBL] [Abstract][Full Text] [Related]
5. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
[TBL] [Abstract][Full Text] [Related]
6. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model.
Gao X; Zhao Y; Stemmer-Rachamimov AO; Liu H; Huang P; Chin S; Selig MK; Plotkin SR; Jain RK; Xu L
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):14676-81. PubMed ID: 26554010
[TBL] [Abstract][Full Text] [Related]
7. An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth.
Bonne NX; Vitte J; Chareyre F; Karapetyan G; Khankaldyyan V; Tanaka K; Moats RA; Giovannini M
J Neurooncol; 2016 Aug; 129(1):47-56. PubMed ID: 27177628
[TBL] [Abstract][Full Text] [Related]
8. Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2.
Choi JW; Lee JY; Phi JH; Wang KC; Chung HT; Paek SH; Kim DG; Park SH; Kim SK
J Neurosurg Pediatr; 2014 Jun; 13(6):650-7. PubMed ID: 24724714
[TBL] [Abstract][Full Text] [Related]
9. Bilateral intracochlear schwannomas in a patient with no genetic or clinical features of neurofibromatosis type 2.
Withers S; Plontke SK; Boeddinghaus R; Kuthubutheen J; Atlas M
HNO; 2020 Jan; 68(Suppl 1):60-64. PubMed ID: 31598774
[TBL] [Abstract][Full Text] [Related]
10. Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2.
Meijer OW; Vandertop WP; Lagerwaard FJ; Slotman BJ
Neurosurgery; 2008 May; 62(5 Suppl):A37-42; discussion A42-3. PubMed ID: 18580779
[TBL] [Abstract][Full Text] [Related]
11. [Bilateral intracochlear schwannomas in a patient with no genetic or clinical features of neurofibromatosis type 2. German version].
Withers S; Plontke SK; Boeddinghaus R; Kuthubutheen J; Atlas M
HNO; 2020 Jul; 68(7):534-538. PubMed ID: 31758201
[TBL] [Abstract][Full Text] [Related]
12. Cochlear implantation in patients with neurofibromatosis type 2 and bilateral vestibular schwannoma.
Lustig LR; Yeagle J; Driscoll CL; Blevins N; Francis H; Niparko JK
Otol Neurotol; 2006 Jun; 27(4):512-8. PubMed ID: 16791043
[TBL] [Abstract][Full Text] [Related]
13. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.
Gehlhausen JR; Park SJ; Hickox AE; Shew M; Staser K; Rhodes SD; Menon K; Lajiness JD; Mwanthi M; Yang X; Yuan J; Territo P; Hutchins G; Nalepa G; Yang FC; Conway SJ; Heinz MG; Stemmer-Rachamimov A; Yates CW; Wade Clapp D
Hum Mol Genet; 2015 Jan; 24(1):1-8. PubMed ID: 25113746
[TBL] [Abstract][Full Text] [Related]
14. Natural history of vestibular schwannomas and hearing loss in NF2 patients.
Peyre M; Bernardeschi D; Sterkers O; Kalamarides M
Neurochirurgie; 2018 Nov; 64(5):342-347. PubMed ID: 26183546
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
[TBL] [Abstract][Full Text] [Related]
16. Management of hearing in pediatric NF2.
Shepard TH; Tucci DL; Grant GA; Kaylie DM
Otol Neurotol; 2012 Aug; 33(6):1066-70. PubMed ID: 22710553
[TBL] [Abstract][Full Text] [Related]
17. Cochlear implantation in neurofibromatosis type 2 after radiation therapy.
Trotter MI; Briggs RJ
Otol Neurotol; 2010 Feb; 31(2):216-9. PubMed ID: 19887974
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
Sponghini AP; Platini F; Rondonotti D; Soffietti R
Tumori; 2015 Nov; 101(6):e167-70. PubMed ID: 26108240
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
20. Vestibular Schwannoma Excision in Sporadic versus Neurofibromatosis Type 2 Populations.
Mahboubi H; Maducdoc MM; Yau AY; Ziai K; Ghavami Y; Badran KW; Al-Thobaiti M; Brandon B; Djalilian HR
Otolaryngol Head Neck Surg; 2015 Nov; 153(5):822-31. PubMed ID: 25791708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
